<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02044185</url>
  </required_header>
  <id_info>
    <org_study_id>CMC-SGC-Lymphoma-LAB-01</org_study_id>
    <nct_id>NCT02044185</nct_id>
  </id_info>
  <brief_title>Clinical Implications of HMGB1 in Patients Treated With Chemotherapy or Hematopoietic Stem Cell Transplantation</brief_title>
  <acronym>CHIP-SCT</acronym>
  <official_title>Observational Study for Clinical Implications of HMGB1 (High-mobility Group Protein B1) in Patients Treated With Chemotherapy or Hematopoietic Stem Cell Transplantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seoul St. Mary's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Seoul St. Mary's Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Acute Graft-versus-host disease(aGVDH) after allogeneic hematopoietic stem cell
      transplantation is one of the meaningful issues in aspect of patient's recovery and survival.
      in recent years, the understanding of the pathology of GVHD is much important to prevent or
      treat aGVHD. additionally, (oral) mucositis is one of the problems in patients with high dose
      chemotherapy, and mucositis by high-dose chemotherapy is related to HMGB-1 as proinflamtory
      cytokines. HMGB1 is a nuclear protein acts as a transcription factor, but, if it was released
      to the outside of cells by damaged cell or necrotic tissues, it works as cytokines for
      promoter of inflammation and cancers. at this point, there are no reported articles about
      correlation of HMGB1 and aGVHD in human. recently, we have seen excessive secretion of serum
      HMGB1 in mouse model, then base on this results, we will check correlation of HMGB1 and
      aGVHD/ oral mucositis in human.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      1. materials 1) inclusion criteria

             1. over 18-year-old

             2. patients with myeloablative conditioning regimen

             3. autologous transplant

             4. patients with confirmation of acute GVHD as over grade II

             5. patients with salvage chemotherapy

                2) exclusion criteria

             1. old age ( over 60-year-old)

             2. patients with reduced intensity stem cell transplantation

        2. method 1) check the serum level of HMGB1, TNF-a, IL-1b, IL-6, Th1, Th2, Th17, FoxP3 on
           7-day before transplant day(D-7), transplant day(D0), 7-day after transplant(D+7), D+14,
           D+21. 2) check the immunohistochemistry level of tissue in diagnosed aGVHD ( performed
           sigmoidoscopy and random biopsy of gut is routine process in our center) 3) check the
           oral mucositis grades (using WHO grading system, NCI -CTC ver.3 scoring system)

        3. analysis 1) student t-test , chi-square test 2) survival analysis
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>January 2014</start_date>
  <completion_date type="Anticipated">December 2015</completion_date>
  <primary_completion_date type="Anticipated">December 2015</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>comparison of serum HMGB1 level before and after diagnosed acute GVHD</measure>
    <time_frame>6 months</time_frame>
    <description>day 7 before stem cell transplantation(SCT), day 0, day 7, 14 after SCT, and date of diagnosed acute GVHD in all patients.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>serum level of immunosuppressive drugs in patients with acute GVHD</measure>
    <time_frame>3 months</time_frame>
    <description>day 7 before stem cell transplantation(SCT), day 0, day 7, 14 after SCT, and date of diagnosed acute GVHD in all patients.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>tissue IHC stain level of biopsy samples of diagnosed acute GVHD</measure>
    <time_frame>if patients diagnosed with acute GVHD will be performed random biopy of colon or stomach.</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>oral mucositis</measure>
    <time_frame>1 month</time_frame>
    <description>find-out the correlation HMGB1 level and oral mucositis grading</description>
  </other_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Acute Graft-versus-host Disease</condition>
  <arm_group>
    <arm_group_label>high dose chemotherapy</arm_group_label>
    <description>group of using myeloablation regimen, autologous stell cell transplantation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>control group</arm_group_label>
    <description>normal population with health screening</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>salvage chemotherapy, total body irradiation</intervention_name>
    <description>there are no direct interventions to our patients.</description>
    <arm_group_label>high dose chemotherapy</arm_group_label>
    <arm_group_label>control group</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      blood plasma biopsy tissue samples of colon
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        1. patients with bone marrow transplantation of patients with acute leukemia, lymphoma in
             patients group

          2. normal populations in Health Promotion Center in control group
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        1. Inclusion Criteria:

               1. over 18-year-old

               2. patients with myeloablative conditioning regimen

               3. autologous transplant

               4. patients with confirmation of acute GVHD as over grade II

               5. patients with salvage chemotherapy

          2. Exclusion Criteria:

               1. very old age ( over 75-year-old)

               2. patients with reduced intensity stem cell transplantation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>seok-goo CHO, M.D,Ph.D</last_name>
    <role>Study Chair</role>
    <affiliation>The Catholic University of Korea</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>young-woo JEON, bachelor, MD</last_name>
    <phone>821042324067</phone>
  </overall_contact>
  <location>
    <facility>
      <name>Seoul St.Mary's hospital</name>
      <address>
        <city>Seoul</city>
        <zip>137701</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hyo-jin KIM</last_name>
      <phone>822225880212</phone>
      <email>irbcumc@catholic.ac.kr</email>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <reference>
    <citation>Brennan TV, Lin L, Huang X, Cardona DM, Li Z, Dredge K, Chao NJ, Yang Y. Heparan sulfate, an endogenous TLR4 agonist, promotes acute GVHD after allogeneic stem cell transplantation. Blood. 2012 Oct 4;120(14):2899-908. doi: 10.1182/blood-2011-07-368720. Epub 2012 Jul 3.</citation>
    <PMID>22760779</PMID>
  </reference>
  <reference>
    <citation>Kornblit B, Masmas T, Petersen SL, Madsen HO, Heilmann C, Schejbel L, Sengeløv H, Müller K, Garred P, Vindeløv L. Association of HMGB1 polymorphisms with outcome after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2010 Feb;16(2):239-52. doi: 10.1016/j.bbmt.2009.10.002. Epub 2009 Oct 9.</citation>
    <PMID>19819342</PMID>
  </reference>
  <reference>
    <citation>Jube S, Rivera ZS, Bianchi ME, Powers A, Wang E, Pagano I, Pass HI, Gaudino G, Carbone M, Yang H. Cancer cell secretion of the DAMP protein HMGB1 supports progression in malignant mesothelioma. Cancer Res. 2012 Jul 1;72(13):3290-301. doi: 10.1158/0008-5472.CAN-11-3481. Epub 2012 May 2.</citation>
    <PMID>22552293</PMID>
  </reference>
  <reference>
    <citation>Kang R, Zhang Q, Zeh HJ 3rd, Lotze MT, Tang D. HMGB1 in cancer: good, bad, or both? Clin Cancer Res. 2013 Aug 1;19(15):4046-57. doi: 10.1158/1078-0432.CCR-13-0495. Epub 2013 May 30. Review.</citation>
    <PMID>23723299</PMID>
  </reference>
  <verification_date>April 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 21, 2014</study_first_submitted>
  <study_first_submitted_qc>January 21, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 23, 2014</study_first_posted>
  <last_update_submitted>April 21, 2015</last_update_submitted>
  <last_update_submitted_qc>April 21, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 22, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Seoul St. Mary's Hospital</investigator_affiliation>
    <investigator_full_name>JEON YOUNG-WOO</investigator_full_name>
    <investigator_title>medical doctor, fellowship</investigator_title>
  </responsible_party>
  <keyword>HMGB1 Protein</keyword>
  <keyword>Graft versus Host Disease</keyword>
  <keyword>Immunosuppressive Agents</keyword>
  <keyword>oral mucositis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Graft vs Host Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

